Published in Front Biosci on May 01, 2007
Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer (2012) 6.82
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A (2010) 3.37
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01
Central melanin-concentrating hormone influences liver and adipose metabolism via specific hypothalamic nuclei and efferent autonomic/JNK1 pathways. Gastroenterology (2012) 1.58
The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care (2009) 1.52
The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci U S A (2009) 1.28
Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases. Mediators Inflamm (2013) 1.27
Effects of water stress on respiration in soybean leaves. Plant Physiol (2005) 1.20
Cytokines in the pathogenesis of cancer cachexia. Curr Opin Clin Nutr Metab Care (2003) 1.20
Cancer cachexia: the molecular mechanisms. Int J Biochem Cell Biol (2003) 1.18
The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol (2005) 1.16
Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats. FEBS Lett (2004) 1.16
Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res (2004) 1.15
Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics. Cell Stem Cell (2013) 1.14
Muscle wasting in cancer: the role of mitochondria. Curr Opin Clin Nutr Metab Care (2015) 1.13
Impact on fatty acid metabolism and differential localization of FATP1 and FAT/CD36 proteins delivered in cultured human muscle cells. Am J Physiol Cell Physiol (2005) 1.13
Molecular mechanisms involved in muscle wasting in cancer and ageing: cachexia versus sarcopenia. Int J Biochem Cell Biol (2004) 1.12
IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol (2006) 1.11
Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers. PLoS One (2012) 1.10
Cross-talk between skeletal muscle and adipose tissue: a link with obesity? Med Res Rev (2005) 1.10
Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett (2005) 1.09
Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle (2011) 1.09
Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future. Nutrition (2005) 1.03
Redox balance and carbonylated proteins in limb and heart muscles of cachectic rats. Antioxid Redox Signal (2010) 1.02
Effects of interleukin-15 (IL-15) on adipose tissue mass in rodent obesity models: evidence for direct IL-15 action on adipose tissue. Biochim Biophys Acta (2002) 1.01
Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett (2006) 1.00
The role of uncoupling proteins in pathophysiological states. Biochem Biophys Res Commun (2002) 0.98
Are there any benefits of exercise training in cancer cachexia? J Cachexia Sarcopenia Muscle (2012) 0.98
Novel approaches to the treatment of cachexia. Drug Discov Today (2007) 0.98
Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise. J Cachexia Sarcopenia Muscle (2011) 0.97
The neuronal influence on tumor progression. Biochim Biophys Acta (2011) 0.96
Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr (2007) 0.96
Formoterol in the treatment of experimental cancer cachexia: effects on heart function. J Cachexia Sarcopenia Muscle (2014) 0.96
Elevated concentration of asymmetric dimethylarginine (ADMA) in individuals with metabolic syndrome. Nitric Oxide (2011) 0.96
Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening. Cell Oncol (Dordr) (2011) 0.95
Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load. Biochim Biophys Acta (2006) 0.95
Antiplatelet, anticoagulant, and fibrinolytic activity in vitro of extracts from selected fruits and vegetables. Blood Coagul Fibrinolysis (2011) 0.95
Hemostasis alterations in metabolic syndrome (review). Int J Mol Med (2006) 0.95
The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle (2011) 0.94
The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia. FEBS Lett (2006) 0.94
Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine. Biochim Biophys Acta (2006) 0.94
Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs. Obesity (Silver Spring) (2008) 0.94
Myostatin: more than just a regulator of muscle mass. Drug Discov Today (2012) 0.93
Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. Obesity (Silver Spring) (2010) 0.93
Cytokines as mediators and targets for cancer cachexia. Cancer Treat Res (2006) 0.93
Anti-inflammatory therapies in cancer cachexia. Eur J Pharmacol (2011) 0.93
TNF-alpha modulates cytokine and cytokine receptors in C2C12 myotubes. Cancer Lett (2002) 0.92
Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer. Cancer Res (2013) 0.92
Mitochondrial and sarcoplasmic reticulum abnormalities in cancer cachexia: altered energetic efficiency? Biochim Biophys Acta (2013) 0.91
Fractions of aqueous and methanolic extracts from tomato (Solanum lycopersicum L.) present platelet antiaggregant activity. Blood Coagul Fibrinolysis (2012) 0.91
Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. Int J Biochem Cell Biol (2008) 0.90
Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog (2012) 0.90
Therapeutic potential of interleukin-15: a myokine involved in muscle wasting and adiposity. Drug Discov Today (2008) 0.90
Activation of UCPs gene expression in skeletal muscle can be independent on both circulating fatty acids and food intake. Involvement of ROS in a model of mouse cancer cachexia. FEBS Lett (2005) 0.90
The pivotal role of cytokines in muscle wasting during cancer. Int J Biochem Cell Biol (2005) 0.89
Sirtuin 1 in skeletal muscle of cachectic tumour-bearing rats: a role in impaired regeneration? J Cachexia Sarcopenia Muscle (2011) 0.89
Tumour necrosis factor-alpha uncouples respiration in isolated rat mitochondria. Cytokine (2003) 0.89
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2. J Cell Physiol (2012) 0.88
Effects of CRF2R agonist on tumor growth and cachexia in mice implanted with Lewis lung carcinoma cells. Muscle Nerve (2008) 0.88
Cancer cachexia: physical activity and muscle force in tumour-bearing rats. Oncol Rep (2011) 0.87
Evaluation of metabolic syndrome in adults of Talca city, Chile. Nutr J (2008) 0.87
Changes in mitochondrial electron partitioning in response to herbicides inhibiting branched-chain amino acid biosynthesis in soybean. Plant Physiol (2003) 0.87
Nuclear magnetic resonance in conjunction with functional genomics suggests mitochondrial dysfunction in a murine model of cancer cachexia. Int J Mol Med (2010) 0.87
Cachexia: a problem of energetic inefficiency. J Cachexia Sarcopenia Muscle (2014) 0.86
Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr Opin Support Palliat Care (2007) 0.86
The pharmacological treatment of cachexia. Curr Drug Targets (2004) 0.86
The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia. Int J Oncol (2007) 0.86
Antiproteolytic effects of plasma from hibernating bears: a new approach for muscle wasting therapy? Clin Nutr (2007) 0.85
L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. Clin Nutr (2012) 0.85
GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images. Genome Biol (2014) 0.85
Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models. J Lipid Res (2013) 0.84
Resveratrol does not ameliorate muscle wasting in different types of cancer cachexia models. Clin Nutr (2007) 0.84
Role of PPARs in inflammatory processes associated with metabolic syndrome (Review). Mol Med Rep (2013) 0.84
Tumor promoting effects of CD95 signaling in chemoresistant cells. Mol Cancer (2010) 0.84
Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect. Int J Mol Med (2005) 0.84
Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. Int J Oncol (2013) 0.84